Last reviewed · How we verify
CN54gp140 glycoprotein-hsp70 conjugate vaccine
CN54gp140 glycoprotein-hsp70 conjugate vaccine is a Biologic drug developed by St George's, University of London. It is currently in Phase 1 development. Also known as: ZM96gp140 glycoprotein.
At a glance
| Generic name | CN54gp140 glycoprotein-hsp70 conjugate vaccine |
|---|---|
| Also known as | ZM96gp140 glycoprotein |
| Sponsor | St George's, University of London |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CN54gp140 glycoprotein-hsp70 conjugate vaccine CI brief — competitive landscape report
- CN54gp140 glycoprotein-hsp70 conjugate vaccine updates RSS · CI watch RSS
- St George's, University of London portfolio CI
Frequently asked questions about CN54gp140 glycoprotein-hsp70 conjugate vaccine
What is CN54gp140 glycoprotein-hsp70 conjugate vaccine?
CN54gp140 glycoprotein-hsp70 conjugate vaccine is a Biologic drug developed by St George's, University of London.
Who makes CN54gp140 glycoprotein-hsp70 conjugate vaccine?
CN54gp140 glycoprotein-hsp70 conjugate vaccine is developed by St George's, University of London (see full St George's, University of London pipeline at /company/st-george-s-university-of-london).
Is CN54gp140 glycoprotein-hsp70 conjugate vaccine also known as anything else?
CN54gp140 glycoprotein-hsp70 conjugate vaccine is also known as ZM96gp140 glycoprotein.
What development phase is CN54gp140 glycoprotein-hsp70 conjugate vaccine in?
CN54gp140 glycoprotein-hsp70 conjugate vaccine is in Phase 1.
Related
- Manufacturer: St George's, University of London — full pipeline
- Also known as: ZM96gp140 glycoprotein
- Compare: CN54gp140 glycoprotein-hsp70 conjugate vaccine vs similar drugs
- Pricing: CN54gp140 glycoprotein-hsp70 conjugate vaccine cost, discount & access